ZGNX Projected Dividend Yield

Zogenix Inc. ( NASDAQ : ZGNX )

Zogenix is a global pharmaceutical company engaged in developing and commercializing therapies to improve the lives of patients and their families living with rare diseases. Co. is focused on developing and commercializing Fintepla, a low-dose fenfluramine, for pediatric epilepsy disorders and MT1621 for mitochondrial depletion disease, thymidine kinase 2 deficiency. In the United Kingdom, Fintepla is under late-stage development in Japan for the treatment of seizures associated with Dravet syndrome, a pediatric epilepsy disorder. Fintepla is also under late-stage development for the treatment of seizures associated with Lennox-Gastaut syndrome, another form of childhood-onset epilepsy.

20 YEAR PERFORMANCE RESULTS